A carregar...
Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
PURPOSE: The programmed death ligand 1 (PD-L1) SP142 assay with a 1% immune cell (IC) cutoff is approved for the selection of advanced triple-negative breast cancer (TNBC) patients for atezolizumab treatment. We aimed to evaluate the interobserver concordance of PD-L1 scoring and inter-assay variabi...
Na minha lista:
| Publicado no: | J Breast Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Korean Breast Cancer Society
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8250096/ https://ncbi.nlm.nih.gov/pubmed/34128367 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4048/jbc.2021.24.e29 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|